ERBB2 and neoplasm: One 10 mg/kg dose of cross-reactive anti-VEGF antibody B20-4.1 decreased tumor trastuzumab uptake by 50% after 2 days in a xenograft HER2-positive breast cancer model (KPL-4) [61].